

# CMR reporting – clinical practice, unmet need

Professor James Moon

CMR lead

Barts Heart Centre UCL, London



# DOI

Corelab director (using AI for pharma studies)

# Clinical care: the clinic room

Make/confirm diagnosis(es)

- Accuracy:
  - sub-types & exclude phenocopies
  - Know what normal is

Assess symptoms

- mechanisms & plan treatment

Evaluate prognostic risks

- SCD, stroke, heart failure

Family screening

- genetics and altered diagnosis thresholds

Choose and agree on the right precision therapy

- mitigate/cure underlying pathophysiology

Monitor disease response

- Precision:
  - for interval change

# Imaging key to cardiac diagnoses

Heart locked away in the chest

We almost never biopsy it

Only 2 blood biomarkers

- BMP, troponin

ECG/functional tests useful but remote from underpinning biology

Genetics

- only now emerging
- tells you lifetime risk

# Diagnosis + therapy = improved outcomes

## The CMR report at the heart of care

- signalling two things:

- the findings
- uncertainty

- BUT

Clinicians don't just report findings – trying to influence care

Pre-test probability (Bayes' theorem)

- patient biology, other results, barriers to testing (too high/too low)

Measurement imprecision

- CMR, other imaging

Distance of measurements from biology and pathways

Poor Standardization

Poor integration with other data


Poor linking to therapy

# Human reporting behaviour

## Clinicians

- not objectively reporting  
eg the ejection fraction
- trying to influence outcomes  
for this patient  
for the service

Humans distort results and vary attention




N=1500 AI vs humans measuring EF

This model: more precise than humans

Yet

- humans skew the graphs at 35-40% and at 55-60%
- Human EF was BETTER predictor than machine (!)

# Current CMR workflows



Total acquisition time AT/ scan = 45 mins  
Capacity per scanner/ day = 13 scans  
Volume/scanner/year = 3,315

Total reporting time = 35 mins  
Capacity per consultant 4 hour session = 6.2 scans  
Total scans per year about 272 scans per session

# Future workflows


Scan request

Scan acquisition



AI deployed acquisition  
(1 Expert radiographer)  
(30 mins)

Reporting software  
Reliant on **high spec hardware with co-managed server**



Automated image manipulation  
AI measurements with human QC  
(1 minute)

Gadgetron Inline AI, Cine Analysis			
Heart rate : 58 bpm; BSA : 2.3 (m²)			
EF (%) : 77.5		EDVI (ml/m²): 99.4	
EDV (ml) : 224.1		ESVi (ml/m²) : 22.3	
ESV (ml) : 50.3		SVI (ml/m²) : 77.1	
SV (ml) : 173.8		MASS (g) : 142.2	
MASS (g) : 142.2		MASSI (g/m²) : 63.1	
CO (L/min) : 10.2		CI (L/min/m²) : 4.5	
MCF (%) : 116.4			
MCF: myocardial contraction fraction			
CI: cardiac index			



Expert interpretation  
(10 minutes)

Total TAT/ scan = 30 mins

Capacity per scanner/ day = 19 scans

Volume/scanner/year = 4,875

(7 day week working = 6,650)


Total reporting time = 11 mins

Capacity per consultant 4 hour session = 15 scans

Total scans per year about 675 scans per session



# Improve outcomes? The Efficacy of Diagnostic Imaging



# Need to understand

The normal heart

The abnormal heart

Measurement science

Existing tests

Existing care

What does the heart have to do? (My list)

Be built



Grow

Low energy at rest


High output at stress

Adapt

Evolutionary toolkit



## The Myocyte



~13 contractile proteins

5000 proteins


Of ~26000 genes

Mutate each one: 15% - cardiac phenotype

Normal vs titin

# A pair of cells: the Myocyte and Capillary

Fundamental building block





[Am J Respir Crit Care Med.](#) 2017 Oct 15;196(8):1075-1077.

**Right Ventricle Vasculature in Human Pulmonary Hypertension Assessed by Stereology.**




## Myocytes into Fibrils




Myoarchitectural disarray of hypertrophic cardiomyopathy begins pre-birth

# The beating heart

Cardiac function




# Disease – a framework



## Here Fabrys




# Current cardiology defined too much by Structure and function



Structure/function a long way away from biology

# Test measurement milestones

- 
1. Technical development and theoretical basis of test
  2. Direct comparison (eg biopsy, animal models, human autopsy)
  3. Detection of changes in established disease compared to normals
  4. Correlation with known cardiac markers of (eg echo, imaging parameters)
  5. Correlation with known biomarkers (eg blood biomarkers)
  6. Demonstration of the test in more than one clinical scenario
  7. Demonstration of test sensitivity (early disease or with age)
  8. Demonstration of the ability to track change (with time, after Rx)
  9. Demonstration of predictive or prognostic value of the test
  10. Standardisation of the test
  11. Development of robust age/ethnic normal reference ranges
  12. Changes in biomarker remain tied to the disease after treatment
  13. Demonstration of the test as a surrogate trial endpoint.
  14. Clinical use and regulatory approval of the test.
  15. Proof test use improves clinical outcome

## A major new test:

## Log study size


1

2

3

4

5



# Understand Metrology - What is good test?

Truth standards - None for the heart

Plausibility

- Clinical does it look right? Agreement with clinician
  - cannot be “superhuman”
- Scientific
  - logical basis (eg of geometric assumptions)
- Social
  - cost/convenience/control/applicability/risk/availability


Precision

- Repeatability
  - interstudy not interobserver
  - smallest detectable difference,
  - power calculation

Biology

- Correlations, predictive power
  - causality, treatment target, interval change

# Accuracy vs Precision




Where am I now?

Vs

Where am I heading?

Our tests not very good:  
Here Precision: Scan Re-scan Repeatability



Cardio-toxicity  
definition: a 10% fall

# Cardiology strategies

Ms AB



77yrs♀

2013


Breast Ca + mets  
Her2 +ve

R<sub>x</sub>

Surgery + Chemo  
then  
Herceptin for life  
+ cardiac monitoring


~55,000 patients pa  
Infarction, heart failure,  
cardiomyopathy  
1 million echos  
100,000 CMR

## Current




## Future Phase 1

Machine analysis  
+40% precision




## Future: Phase 2

+ Autonomous scanning  
+ New imaging biomarkers



# CMR Quantitative AI tool development





# The CMR report

The data integration point between signal acquisition and the doctor:patient relationship

Bayes' theorem: Pretest probability + test change in probability

- Clear signal:
  - Above threshold: treat
  - Below threshold: no treat (discharge)
- Poor signal:
  - Repeat at Interval

Imaging timing: Two key processes:

- first visit: baseline description (diagnosis - accuracy)
- follow-up: depends on reason: either interval change (precision) or reassess (accuracy)

Clinician actions: two domains: for a patient; for the service

- For the patient:
  - Comparison with thresholds: normal vs abnormal
  - Communication of uncertainty
  - Influence care decisions
- For a service:
  - Efficiency, higher goals